Avocatin B Protects Against Lipotoxicity and Improves Insulin Sensitivity in Diet-Induced Obesity
Molecular Nutrition & Food Research, 2019
Therapeutic agents that are safe and eﬀectively inhibit fatty acid oxidation (FAO) and improve diet-induced obesity (DIO)-associated pathologies are currently not available. AvoB’s mechanism of action and favorable safety proﬁle highlight its nutritional and clinical importance.
Avocado-derived polyols for use as novel co-surfactants in low energy self-emulsifying microemulsions
Scientific Reports, March 27, 2020
Avocado (Persea americana Mill.; Lauraceae) seed-derived polyhydroxylated fatty alcohols (PFAs) or polyols (i.e., avocadene and avocadyne) are metabolic modulators that selectively induce apoptosis of leukemia stem cells and reverse pathologies associated with diet-induced obesity.A pilot pharmacokinetic evaluation of an AvoB formulation in C57BL/6J mice revealed appreciable accumulation in whole blood and biodistribution in key target tissues. Lastly, incorporation of AvoB in SEDDS significantly improved encapsulation of the poorly water-soluble drugs naproxen and curcumin.
A meta‐analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity
Clinical Obesity, May 21, 2019
Chromium supplementation was associated with some improvements in body composition in subjects with obesity/overweight. The effect size was medium and the clinical relevance of chromium as a weight loss aid remains uncertain. Further investigation from larger and well‐designed randomized controlled studies, especially in patients with diabetes, is warranted.
Systematic review and meta‐analysis of the efficacy and safety of chromium supplementation in diabetes
Journal of Clinical Pharmacy and Therapeutics, March 17, 2014
The available evidence suggests favourable effects of chromium supplementation on glycaemic control in patients with diabetes. Chromium monosupplementation may additionally improve triglycerides and HDL‐C levels. Chromium supplementation at usual doses does not increase the risk of adverse events compared with placebo. Data on chromium combined supplementation are limited and inconclusive. Long‐term benefit and safety of chromium supplementation remain to be further investigated.